Calcium Sensitizing Drugs, Phosphodiesterase 3 Inhibitors, and Omecamtiv Mecarbil and their Role in Heart Failure

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorGinini, Adi
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentMegyeri, Attila
dc.contributor.opponentDrimba, László
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás Tanszék
dc.date.accessioned2023-07-20T09:09:46Z
dc.date.available2023-07-20T09:09:46Z
dc.date.created2023-06
dc.description.abstractHeart failure is a prevalent and complex medical condition affecting over 60 million patients worldwide, and poses a significant risk of mortality in the elderly. The calcium sensitizing drug levosimendan and the phosphodiesterase 3 inhibitor milrinone are among the inotropic drugs which are currently employed in clinical practice to treat heart failure, whereas the myosin activator drug omecamtive mecarbil has not yet been approved for use in Europe and the United States despite the promising potential to reduce the mortality in severe heart failure patients. Levosimendan has been shown to improve survival rate and reduce hospitalization duration thanks to its inotropic and cardioprotective effects, however, caution should be taken when used in hypotensive patients. According to the guidelines, the use of milrinone should be limited to short-term use due to the potential arrhythmogenic effects which may result from the alteration of intracellular calcium.
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent55
dc.identifier.urihttps://hdl.handle.net/2437/357729
dc.language.isoen
dc.subjectHeart failure
dc.subjectCalcium Sensitizing Drugs
dc.subjectPhosphodiesterase 3 Inhibitors
dc.subjectOmecamtiv Mecarbil
dc.subjectCardiac contractility
dc.subjectCardiac output
dc.subjectClinical trials
dc.subjectDrug efficacy
dc.subjectAdverse effects
dc.subject.dspaceDEENK Témalista::Orvostudomány::Farmakológia
dc.titleCalcium Sensitizing Drugs, Phosphodiesterase 3 Inhibitors, and Omecamtiv Mecarbil and their Role in Heart Failure
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)